doi: 10.1016/j.atherosclerosis.2011.12.042. Unable to load your collection due to an error 2019 Jul;34(4):723-771. doi: 10.3904/kjim.2019.188. The combination group showed greater reductions in TG and elevation in HDL-cholesterol. doi: 10.1371/journal.pone.0205006. The purpose of this study is to determine effects of combination therapy with rosuvastatin and fenofibrate on atheromatous plaques and its tissue characteristics of de novo coronary lesions with intermediate stenosis in patient with coronary artery disease, compared with rosuvastatin alone therapy. 2006 Jun;28(6):933-42. doi: 10.1016/j.clinthera.2006.06.004.Catapano AL, Davidson MH, Ballantyne CM, Brady WE, Gazzara RA, Tomassini JE, Tershakovec AM.Curr Med Res Opin. 2004 Sep;26(9):1368-87. doi: 10.1016/j.clinthera.2004.09.005.Li F, Zheng X, Bao Y, Chen T, Zeng J, Xu X, Yan C, Feng L.Drug Des Devel Ther. Atorvastatin rated 4.4/10 vs Fenofibrate rated 5.8/10 in … A total of 216 patients with total cholesterol >/=200 mg/dl (>/=5.17 mmol/l) and triglycerides >/=200 and <800 mg/dl (>/=2.26 and <9.03 mmol/l) were randomised to one of two placebo groups, rosuvastatin 5 mg or rosuvastatin 10 mg for 6 weeks (fixed-dose phase). eCollection 2018.Han JS, Kim K, Jung Y, Lee JH, Namgung J, Lee HY, Suh J, Hwang GS, Lee SH.Sci Rep. 2018 Oct 2;8(1):14642. doi: 10.1038/s41598-018-33058-x. This site needs JavaScript to work properly. Epub 2012 Mar 19.Polenova NV, Vaulin NA, Masenko VP, Iavelov IS, Gratsianskiĭ NA.Expert Opin Investig Drugs. Elsevier Science Leukocyte count and hemoglobin level decreased to a greater extent in the combination group. Background: Statin and ezetimibe combination therapy may be insufficient to improve lipid and nonlipid parameters beyond low-density lipoprotein cholesterol (LDL-C) in patients with mixed dyslipidemia. eCollection 2019.Indian J Endocrinol Metab. Elsevier Science 2012 Apr 1;12(2):117-25. doi: 10.2165/11597940-000000000-00000.Makariou SE, Liberopoulos EN, Agouridis AP, Challa A, Elisaf M.J Cardiovasc Pharmacol Ther. Another combination of fenofibric acid and rosuvastatin is in clinical development for the treatment of dyslipidaemia. Please enable it to take advantage of the complete set of features! During the subsequent 18-week dose-titration phase, one placebo group received titrated rosuvastatin 10, 20 and 40 mg (placebo/rosuvastatin); one placebo group received titrated fenofibrate 67 mg once, twice and three times daily (placebo/fenofibrate); and patients receiving 5 or 10 mg rosuvastatin received titrated fenofibrate as above (rosuvastatin 5mg/fenofibrate and rosuvastatin 10 mg/fenofibrate groups). Elsevier Science 2017 Jan 7;16(1):4. doi: 10.1186/s12933-016-0486-2.Indian J Endocrinol Metab. At 24 weeks, the placebo/rosuvastatin group and placebo per fenofibrate group had triglyceride reductions of 30.3% versus 33.6%, respectively (P =NS), and LDL cholesterol was reduced by 46.7% in the rosuvastatin group and increased by 0.7% in the fenofibrate group (P <0.001). 2018 Sep-Oct;22(5):627-631. doi: 10.4103/ijem.IJEM_321_16.Cardiol Res. These results indicated that rosuvastatin produces marked reductions in triglycerides and LDL cholesterol when used alone or in combination with fenofibrate in type 2 diabetes patients with elevated cholesterol and triglyceride levels and may constitute a valuable treatment option in the diabetic population. Compare Atorvastatin vs Fenofibrate head-to-head with other drugs for uses, ratings, cost, side effects, interactions and more. Name must be less than 100 characters Unable to load your delegates due to an error In this study we compared the effects of rosuvastatin 10 mg/fenofibrate 160 mg combination and rosuvastatin 10 mg monotherapy on muscle and liver enzyme, homocysteine levels, kidney, blood glucose control, and blood cell counts. Strandberg TE, Feely J, Sigurdsson EL; DISCOVERY study group.Clin Ther. Doses were increased at 6-week intervals if low-density lipoprotein (LDL) cholesterol remained >50 mg/dl (>1.3 mmol/l). 2013 Apr;4(2):47-55. doi: 10.4021/cr270w. 2018 Oct 4;13(10):e0205006. Epub 2019 Aug 7.Rhee EJ, Kim HC, Kim JH, Lee EY, Kim BJ, Kim EM, Song Y, Lim JH, Kim HJ, Choi S, Moon MK, Na JO, Park KY, Oh MS, Han SY, Noh J, Yi KH, Lee SH, Hong SC, Jeong IK.Korean J Intern Med. 2020 May;9(2):283-290. doi: 10.12997/jla.2020.9.2.283. 2005 Jan;59(1):92-101. doi: 10.1111/j.1742-1241.2005.00346.x.Clin Ther. Elsevier Science Name must be less than 100 characters No significant differences in effect on high-density lipoprotein (HDL) were observed among treatment groups. Rosuvastatin is a member of the drug class of statins, used in combination with weight-loss to treat high cholesterol and related conditions, and to prevent cardiovascular disease. eHealthMe has been monitoring drugs since 2008.